Skip to main content
European Commission logo print header

Sustainable production of transgenic strawberry plants. ethnical consequences and potential effect on the producers and consumers.

Obiettivo

The rationale for this project is given by the fact that the pharmaceutical industry is currently undergoing a significant change in strategy in preclinical drug development. Relevant advances are being made in the field of genome analysis with the onset of gene chip technologies permitting high throughput investigations and the use of miniature sample quantities. The same is happening for protease analysis and mass- spectrometry. We want to develop the "missing link" in high throughput testing: A highly controlled high-throughput bioreactor based on the use of engineered miniature in vitro tissue analogues. This will lead to the establishment of a firm correlation between genome, protease and catalytic expressions or biochemical function resulting in a complementary and more predictive picture of drug action.

Invito a presentare proposte

Data not available

Meccanismo di finanziamento

CSC - Cost-sharing contracts

Coordinatore

NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY
Contributo UE
Nessun dato
Indirizzo
NTNU
7491 TRONDHEIM
Norvegia

Mostra sulla mappa

Costo totale
Nessun dato

Partecipanti (2)